A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells
The outbreak of a current public health coronavirus 2019 disease is a causative agent of a serious acute respiratory syndrome and even death. COVID-19 has exposed to multi-suggested pharmaceutical agents to control this global disease. Baricitinib, a well-known antirheumatic agent, was one of...
Main Author: | Abeer M Al-Humaidhi |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Baghdad/ Al-Kindy College of Medicine
2020-07-01
|
Series: | مجله كليه طب الكندي |
Subjects: | |
Online Access: | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/176 |
Similar Items
-
Efficacy of baricitinib in severe coronavirus disease 2019
by: Ahmed M A E F Amer, et al.
Published: (2023-01-01) -
BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01) -
Baricitinib: First Systemic Oral Drug for Alopecia Therapy
by: Prashant Mishra, et al.
Published: (2022-10-01) -
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019-03-01) -
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
by: Vijairam Selvaraj, et al.
Published: (2022-07-01)